FRA
Front Row Advisors’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.64K | Hold |
116
| – | – | ﹤0.01% | 427 |
|
|
2025
Q1 | $3.95K | Hold |
116
| – | – | ﹤0.01% | 422 |
|
|
2024
Q4 | $4.57K | Hold |
116
| – | – | ﹤0.01% | 413 |
|
|
2024
Q3 | $5.45K | Hold |
116
| – | – | ﹤0.01% | 405 |
|
|
2024
Q2 | $6.27K | Hold |
116
| – | – | ﹤0.01% | 685 |
|
|
2024
Q1 | $7.91K | Hold |
116
| – | – | ﹤0.01% | 636 |
|
|
2023
Q4 | $7.26K | Sell |
116
-720
| -86% | -$45.1K | ﹤0.01% | 353 |
|
|
2023
Q3 | $37.9K | Sell |
836
-15,832
| -95% | -$719K | 0.02% | 264 |
|
|
2023
Q2 | $936K | Sell |
16,668
-600
| -3% | -$33.7K | 0.42% | 58 |
|
|
2023
Q1 | $781K | Sell |
17,268
-180
| -1% | -$8.14K | 0.37% | 61 |
|
|
2022
Q4 | $709K | Sell |
17,448
-1,405
| -7% | -$57.1K | 0.37% | 68 |
|
|
2022
Q3 | $1.23M | Sell |
18,853
-287
| -1% | -$18.8K | 0.64% | 52 |
|
|
2022
Q2 | $1.16M | Sell |
19,140
-20
| -0.1% | -$1.22K | 0.57% | 53 |
|
|
2022
Q1 | $1.2M | Buy |
19,160
+100
| +0.5% | +$6.28K | 0.49% | 58 |
|
|
2021
Q4 | $1.44M | Buy |
19,060
+1,294
| +7% | +$98K | 0.54% | 56 |
|
|
2021
Q3 | $1.99M | Buy |
17,766
+225
| +1% | +$25.2K | 0.84% | 38 |
|
|
2021
Q2 | $2.05M | Buy |
17,541
+1,043
| +6% | +$122K | 0.84% | 37 |
|
|
2021
Q1 | $2.01M | Buy |
16,498
+536
| +3% | +$65.3K | 0.97% | 35 |
|
|
2020
Q4 | $2.44M | Sell |
15,962
-195
| -1% | -$29.9K | 1.25% | 20 |
|
|
2020
Q3 | $1.96M | Sell |
16,157
-410
| -2% | -$49.8K | 1.04% | 31 |
|
|
2020
Q2 | $1.22M | Sell |
16,567
-205
| -1% | -$15.1K | 0.76% | 45 |
|
|
2020
Q1 | $825K | Buy |
16,772
+16,722
| +33,444% | +$823K | 0.56% | 52 |
|
|
2019
Q4 | $3K | Hold |
50
| – | – | ﹤0.01% | 704 |
|
|
2019
Q3 | $2K | Hold |
50
| – | – | ﹤0.01% | 772 |
|
|
2019
Q2 | $2K | Hold |
50
| – | – | ﹤0.01% | 815 |
|
|
2019
Q1 | $2K | Buy |
+50
| New | +$2K | ﹤0.01% | 813 |
|